Costs and length of stay of drug-related hospital admissions in cancer patients

Yu Ko, Yong Sheng Gwee, Yu Chu Huang, Joen Chiang, Alexandre Chan

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background Most previous studies of the incidence and economic impact of drug-related hospital admissions were not cancer specific, despite the fact that drug-related problems (DRPs) are of particular concern in oncology. Objective The goals of this study were to assess the economic impact, particularly the length of stay (LOS) and direct medical costs (DMC), of drug-related hospital admissions and the associated factors in cancer patients in Singapore. Methods A prospective study was conducted over a 5-month period in 2 oncology wards at the largest acute tertiary hospital in Singapore. Drug-related admissions were identified from all oncology admissions to these wards, and the demographic, clinical, and cost data of these drug-related admissions were collected. The association between LOS and DMC as well as their associations with age, severity, and preventability of DRPs were examined. A nationwide estimation was made to determine the overall DMC of drug-related hospital admissions among cancer patients. Results A total of 151 drug-related admissions that occurred among 137 cancer patients were identified. The mean DMC (in Singapore dollars [SGD]) and LOS per drug-related admission were SGD $4747 and 6.1 days, respectively. A nationwide extrapolation estimated an annual total DMC of SGD $16.2 million. Longer LOS was found to be correlated with higher DMC (rs = 0.86, P <0.001) and preventable DRPs (P = 0.02). Conclusions Drug-related hospitalization among cancer patients is costly; therefore, more attention is warranted to develop and improve strategies for preventing drug-related morbidity and mortality in cancer patients.

Original languageEnglish
Pages (from-to)588-592
Number of pages5
JournalClinical Therapeutics
Volume36
Issue number4
DOIs
Publication statusPublished - Apr 1 2014
Externally publishedYes

Fingerprint

Length of Stay
Costs and Cost Analysis
Singapore
Pharmaceutical Preparations
Neoplasms
Drug Costs
Economics
Tertiary Care Centers
Hospitalization
Cohort Studies
Demography
Prospective Studies
Morbidity
Mortality

Keywords

  • cancer
  • costs
  • drug-related hospital admissions
  • length of stay

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Costs and length of stay of drug-related hospital admissions in cancer patients. / Ko, Yu; Gwee, Yong Sheng; Huang, Yu Chu; Chiang, Joen; Chan, Alexandre.

In: Clinical Therapeutics, Vol. 36, No. 4, 01.04.2014, p. 588-592.

Research output: Contribution to journalArticle

Ko, Yu ; Gwee, Yong Sheng ; Huang, Yu Chu ; Chiang, Joen ; Chan, Alexandre. / Costs and length of stay of drug-related hospital admissions in cancer patients. In: Clinical Therapeutics. 2014 ; Vol. 36, No. 4. pp. 588-592.
@article{f7844d1b03bc408c90e20b30ad6f1d15,
title = "Costs and length of stay of drug-related hospital admissions in cancer patients",
abstract = "Background Most previous studies of the incidence and economic impact of drug-related hospital admissions were not cancer specific, despite the fact that drug-related problems (DRPs) are of particular concern in oncology. Objective The goals of this study were to assess the economic impact, particularly the length of stay (LOS) and direct medical costs (DMC), of drug-related hospital admissions and the associated factors in cancer patients in Singapore. Methods A prospective study was conducted over a 5-month period in 2 oncology wards at the largest acute tertiary hospital in Singapore. Drug-related admissions were identified from all oncology admissions to these wards, and the demographic, clinical, and cost data of these drug-related admissions were collected. The association between LOS and DMC as well as their associations with age, severity, and preventability of DRPs were examined. A nationwide estimation was made to determine the overall DMC of drug-related hospital admissions among cancer patients. Results A total of 151 drug-related admissions that occurred among 137 cancer patients were identified. The mean DMC (in Singapore dollars [SGD]) and LOS per drug-related admission were SGD $4747 and 6.1 days, respectively. A nationwide extrapolation estimated an annual total DMC of SGD $16.2 million. Longer LOS was found to be correlated with higher DMC (rs = 0.86, P <0.001) and preventable DRPs (P = 0.02). Conclusions Drug-related hospitalization among cancer patients is costly; therefore, more attention is warranted to develop and improve strategies for preventing drug-related morbidity and mortality in cancer patients.",
keywords = "cancer, costs, drug-related hospital admissions, length of stay",
author = "Yu Ko and Gwee, {Yong Sheng} and Huang, {Yu Chu} and Joen Chiang and Alexandre Chan",
year = "2014",
month = "4",
day = "1",
doi = "10.1016/j.clinthera.2014.02.014",
language = "English",
volume = "36",
pages = "588--592",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "4",

}

TY - JOUR

T1 - Costs and length of stay of drug-related hospital admissions in cancer patients

AU - Ko, Yu

AU - Gwee, Yong Sheng

AU - Huang, Yu Chu

AU - Chiang, Joen

AU - Chan, Alexandre

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Background Most previous studies of the incidence and economic impact of drug-related hospital admissions were not cancer specific, despite the fact that drug-related problems (DRPs) are of particular concern in oncology. Objective The goals of this study were to assess the economic impact, particularly the length of stay (LOS) and direct medical costs (DMC), of drug-related hospital admissions and the associated factors in cancer patients in Singapore. Methods A prospective study was conducted over a 5-month period in 2 oncology wards at the largest acute tertiary hospital in Singapore. Drug-related admissions were identified from all oncology admissions to these wards, and the demographic, clinical, and cost data of these drug-related admissions were collected. The association between LOS and DMC as well as their associations with age, severity, and preventability of DRPs were examined. A nationwide estimation was made to determine the overall DMC of drug-related hospital admissions among cancer patients. Results A total of 151 drug-related admissions that occurred among 137 cancer patients were identified. The mean DMC (in Singapore dollars [SGD]) and LOS per drug-related admission were SGD $4747 and 6.1 days, respectively. A nationwide extrapolation estimated an annual total DMC of SGD $16.2 million. Longer LOS was found to be correlated with higher DMC (rs = 0.86, P <0.001) and preventable DRPs (P = 0.02). Conclusions Drug-related hospitalization among cancer patients is costly; therefore, more attention is warranted to develop and improve strategies for preventing drug-related morbidity and mortality in cancer patients.

AB - Background Most previous studies of the incidence and economic impact of drug-related hospital admissions were not cancer specific, despite the fact that drug-related problems (DRPs) are of particular concern in oncology. Objective The goals of this study were to assess the economic impact, particularly the length of stay (LOS) and direct medical costs (DMC), of drug-related hospital admissions and the associated factors in cancer patients in Singapore. Methods A prospective study was conducted over a 5-month period in 2 oncology wards at the largest acute tertiary hospital in Singapore. Drug-related admissions were identified from all oncology admissions to these wards, and the demographic, clinical, and cost data of these drug-related admissions were collected. The association between LOS and DMC as well as their associations with age, severity, and preventability of DRPs were examined. A nationwide estimation was made to determine the overall DMC of drug-related hospital admissions among cancer patients. Results A total of 151 drug-related admissions that occurred among 137 cancer patients were identified. The mean DMC (in Singapore dollars [SGD]) and LOS per drug-related admission were SGD $4747 and 6.1 days, respectively. A nationwide extrapolation estimated an annual total DMC of SGD $16.2 million. Longer LOS was found to be correlated with higher DMC (rs = 0.86, P <0.001) and preventable DRPs (P = 0.02). Conclusions Drug-related hospitalization among cancer patients is costly; therefore, more attention is warranted to develop and improve strategies for preventing drug-related morbidity and mortality in cancer patients.

KW - cancer

KW - costs

KW - drug-related hospital admissions

KW - length of stay

UR - http://www.scopus.com/inward/record.url?scp=84898862543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898862543&partnerID=8YFLogxK

U2 - 10.1016/j.clinthera.2014.02.014

DO - 10.1016/j.clinthera.2014.02.014

M3 - Article

C2 - 24636525

AN - SCOPUS:84898862543

VL - 36

SP - 588

EP - 592

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 4

ER -